A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

BACKGROUND: Metastatic pancreatic adenocarcinoma (PAC) prognosis remains dismal and gemcitabine monotherapy has been the standard treatment over the last decade. Currently, two first-line regimens are used in this setting: FOLFIRINOX and nab-paclitaxel plus gemcitabine. Increasing translational data...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachet, Jean-Baptiste, Chibaudel, Benoist, Bonnetain, Franck, Validire, Pierre, Hammel, Pascal, André, Thierry, Louvet, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596389/
https://www.ncbi.nlm.nih.gov/pubmed/26445094
http://dx.doi.org/10.1186/s12885-015-1656-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596389/
https://www.ncbi.nlm.nih.gov/pubmed/26445094
http://dx.doi.org/10.1186/s12885-015-1656-4

Ejemplares similares